FCM
NVAX icon

Frontier Capital Management’s Novavax NVAX Stock Holding History

Frontier Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,126
Closed -$507K – 325
2016
Q4 		$507K Sell
20,126
-1,324
-6% -$38.6K ﹤0.01% 282
2016
Q3 		$892K Buy
+21,450
New +$2.77M 0.01% 294

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Frontier Capital Management's NVAX Position: Q1 2017 in Review

Frontier Capital Management sold out of Novavax (NVAX) in Q1 2017, closing a stake of 20,126 shares — an estimated $507K sold.

Frontier Capital Management first reported a position in NVAX in Q3 2016 and held it in 2 quarters. The position peaked at $892K in Q3 2016. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

  • Frontier Capital Management reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
  • Frontier Capital Management sold 20,126 Novavax shares in Q1 2017, an estimated $507K.
  • Frontier Capital Management first reported a position in Novavax in Q3 2016 and held it in 2 quarters.
  • Frontier Capital Management's Novavax position peaked at $892K in Q3 2016.
  • 129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on Frontier Capital Management's 13F filing for Q1 2017, filed 10 May 2017.